logo

LSTA

Lisata Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

LSTA fundamentals

Lisata Therapeutics (LSTA) released its earnings on Nov 6, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.49 (YoY +16.95%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.49
+16.95%
Report date
Nov 6, 2025
LSTA Earnings Call Summary for Q3,2025
  • Financial Stability: Operating expenses down 17.3% YoY to $4.4 million; $19M cash runway to Q1 2027.
  • Clinical Momentum: ASCEND trial Cohort A shows 4 complete responses; CENDIFOX pancreatic cancer resection rate 50%.
  • Strategic Expansion: Catalent ADC partnership with preclinical success; GATC AI drug discovery alliance identifies 2026 candidates.
  • Phase III Challenges: ASCEND Phase III funding requires pharma partners; stock underperformance despite positive data.
EPS
Revenue

Revenue & Expenses

Key Indicators

Lisata Therapeutics (LSTA) key financial stats and ratios, covering profitability, financial health, and leverage.
Lisata Therapeutics (LSTA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Lisata Therapeutics (LSTA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Lisata Therapeutics (LSTA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Lisata Therapeutics (LSTA) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Lisata Therapeutics (LSTA) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield